Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245709 · ClinicalTrials.gov registry record · Phase 2
Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Dwight Koeberl, M.D., Ph.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04245709 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Dwight Koeberl, M.D., Ph.D.. The registered enrollment target is 25 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04245709, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Dwight Koeberl, M.D., Ph.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and tolerability of clenbuterol (taken by mouth) in subjects with ALS (amyotrophic lateral sclerosis) and to assess the effectiveness of clenbuterol with regard to motor function in subjects with ALS. Subjects will be in this study approximately 24 weeks. The study drug, clenbuterol, is taken twice a day. As part of this study subjects will have the following tests and procedures: medical history, vital signs, physical examination, blood tests, heart and lung function tests, muscle function test, ALSFRS-R (ALS Functional Rating Scale Revised), thyroid function and for women who can become pregnant, pregnancy tests.
Conditions Studied
Interventions
- DRUG Clenbuterol
Study Locations (1)
North Carolina
- Duke University Medical center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04245709
The ClinicalTrials.gov registry entry for NCT04245709 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Dwight Koeberl, M.D., Ph.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Clenbuterol is the first listed.
NCT04245709 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04245709 about?
NCT04245709 is a clinical study titled "Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis". The purpose of this study is to assess the safety and tolerability of clenbuterol (taken by mouth) in subjects with ALS (amyotrophic lateral sclerosis) and to assess the effectiveness of clenbuterol with regard to motor function in subjects with ALS. Subjects will be in this study approximately 24 w...
What is the current status of trial NCT04245709?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-02-10. Estimated completion is 2021-03-10.
What conditions does trial NCT04245709 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04245709?
The interventions under investigation include: Clenbuterol (DRUG).
Who is sponsoring clinical trial NCT04245709?
This trial is sponsored by Dwight Koeberl, M.D., Ph.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04245709 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.